Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles

被引:42
作者
Rudolf, MP
Nieland, JD
DaSilva, DM
Velders, MP
Müller, M
Greenstone, HL
Schiller, JT
Kast, WM
机构
[1] Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL 60153 USA
[2] Loyola Univ, Dept Immunol & Microbiol, Maywood, IL 60153 USA
[3] NIH, Cellular Oncol Lab, Bethesda, MD 20892 USA
关键词
cervical cancer; CTL; HLA-A*0201; human papilloma virus; vaccine;
D O I
10.1515/BC.1999.045
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has been postulated that upon binding to a cell surface receptor, papilloma virus-like particles (VLPs) gain entry into the cytosol of infected cells and the capsid proteins L1 and L2 can be processed in the MHC class I presentation pathway. Vaccination of mice with human papilloma virus-like particles consisting of capsid proteins L1 and L2 induced a CD8-mediated and perforin dependent protective immune response against a tumor challenge with human papilloma virus transformed tumor cells, which express only minute amounts of L1 protein. Here we show that HPV16 capsid proteins stimulate a MHC class I restricted CTL response with human peripheral blood lymphocytes (PBL) in vitro. The vigorous response was specific for VLP-infected target cells and was MHC class I restricted. Moreover we show the presence of at least one HLA-A*0201 restricted CTL epitope within the HPV-16 capsid proteins by using a VLP-'infected' HLA-A*0201 transfected human cell line as target cells. These results demonstrated that VLPs can induce a HPV16 capsid protein-specific immune response in humans, allowing the monitoring of immune responses induced by vaccines based on chimeric VLPs carrying additional immunogenic peptides or proteins in therapeutical applications in human patients.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 22 条
[1]   L1-specific protection from tumor challenge elicited by HPV16 virus-like particles [J].
De Bruijn, MLH ;
Greenstone, HL ;
Vermeulen, H ;
Melief, CJM ;
Lowy, DR ;
Schiller, JT ;
Kast, WM .
VIROLOGY, 1998, 250 (02) :371-376
[2]   Identification of the alpha(6) integrin as a candidate receptor for papillomaviruses [J].
Evander, M ;
Frazer, IH ;
Payne, E ;
Qi, YM ;
Hengst, K ;
McMillan, NAJ .
JOURNAL OF VIROLOGY, 1997, 71 (03) :2449-2456
[3]   Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model [J].
Greenstone, HL ;
Nieland, JD ;
de Visser, KE ;
De Bruijn, MLH ;
Kirnbauer, R ;
Roden, RBS ;
Lowy, DR ;
Kast, WM ;
Schiller, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) :1800-1805
[4]   HUMAN PAPILLOMAVIRUSES IN THE PATHOGENESIS OF ANOGENITAL CANCER [J].
HAUSEN, HZ .
VIROLOGY, 1991, 184 (01) :9-13
[5]   EFFICIENT SELF-ASSEMBLY OF HUMAN PAPILLOMAVIRUS TYPE-16 L1 AND L1-L2 INTO VIRUS-LIKE PARTICLES [J].
KIRNBAUER, R ;
TAUB, J ;
GREENSTONE, H ;
RODEN, R ;
DURST, M ;
GISSMANN, L ;
LOWY, DR ;
SCHILLER, JT .
JOURNAL OF VIROLOGY, 1993, 67 (12) :6929-6936
[6]   PAPILLOMAVIRUS L1 MAJOR CAPSID PROTEIN SELF-ASSEMBLES INTO VIRUS-LIKE PARTICLES THAT ARE HIGHLY IMMUNOGENIC [J].
KIRNBAUER, R ;
BOOY, F ;
CHENG, N ;
LOWY, DR ;
SCHILLER, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (24) :12180-12184
[7]   VIRAL RESTRICTED CYTOLYTIC LYMPHOCYTE-T RECOGNITION OF HYBRID HUMAN-MURINE CLASS-I HISTOCOMPATIBILITY ANTIGENS [J].
MAZIARZ, RT ;
BURAKOFF, SJ ;
REISS, CS .
CELLULAR IMMUNOLOGY, 1986, 99 (01) :279-286
[8]  
MULLER M, 1995, J VIROL, V69, P948
[9]   Chimeric papillomavirus-like particles [J].
Muller, M ;
Zhou, JA ;
Reed, TD ;
Rittmuller, C ;
Burger, A ;
Gabelsberger, J ;
Braspenning, J ;
Gissmann, L .
VIROLOGY, 1997, 234 (01) :93-111
[10]  
Nimako M, 1997, CANCER RES, V57, P4855